vs
开利（CARR）与吉利德科学（GILD）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是开利的1.6倍（$7.9B vs $4.8B），吉利德科学净利率更高（27.5% vs 1.1%，领先26.5%），开利同比增速更快（33.2% vs 4.7%），吉利德科学自由现金流更多（$3.1B vs $909.0M），过去两年吉利德科学的营收复合增速更高（8.9% vs -11.5%）
开利全球是总部位于美国佛罗里达州棕榈滩花园的跨国企业，成立于1915年，主营暖通空调、制冷、消防及安防设备。公司最初以生产销售暖通空调系统起家，后续逐步拓展业务，覆盖商用制冷、餐饮服务设备及消防安防技术等领域。
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
CARR vs GILD — 直观对比
营收规模更大
GILD
是对方的1.6倍
$4.8B
营收增速更快
CARR
高出28.5%
4.7%
净利率更高
GILD
高出26.5%
1.1%
自由现金流更多
GILD
多$2.2B
$909.0M
两年增速更快
GILD
近两年复合增速
-11.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $4.8B | $7.9B |
| 净利润 | $53.0M | $2.2B |
| 毛利率 | — | 79.5% |
| 营业利润率 | 2.1% | 25.0% |
| 净利率 | 1.1% | 27.5% |
| 营收同比 | 33.2% | 4.7% |
| 净利润同比 | -97.9% | 22.4% |
| 每股收益（稀释后） | $0.07 | $1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CARRGILD
| Q4 25 | $4.8B | $7.9B | ||
| Q3 25 | $5.6B | $7.8B | ||
| Q2 25 | $6.1B | $7.1B | ||
| Q1 25 | $5.2B | $6.7B | ||
| Q4 24 | $3.6B | $7.6B | ||
| Q3 24 | $6.0B | $7.5B | ||
| Q2 24 | $6.7B | $7.0B | ||
| Q1 24 | $6.2B | $6.7B |
净利润CARRGILD
| Q4 25 | $53.0M | $2.2B | ||
| Q3 25 | $428.0M | $3.1B | ||
| Q2 25 | $591.0M | $2.0B | ||
| Q1 25 | $412.0M | $1.3B | ||
| Q4 24 | $2.6B | $1.8B | ||
| Q3 24 | $447.0M | $1.3B | ||
| Q2 24 | $2.3B | $1.6B | ||
| Q1 24 | $269.0M | $-4.2B |
毛利率CARRGILD
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 79.8% | ||
| Q2 25 | — | 78.8% | ||
| Q1 25 | — | 76.9% | ||
| Q4 24 | — | 79.1% | ||
| Q3 24 | — | 79.1% | ||
| Q2 24 | — | 77.8% | ||
| Q1 24 | — | 76.8% |
营业利润率CARRGILD
| Q4 25 | 2.1% | 25.0% | ||
| Q3 25 | 9.7% | 42.8% | ||
| Q2 25 | 14.8% | 34.9% | ||
| Q1 25 | 12.1% | 33.6% | ||
| Q4 24 | -63.6% | 32.4% | ||
| Q3 24 | 12.8% | 11.8% | ||
| Q2 24 | 55.2% | 38.0% | ||
| Q1 24 | 8.1% | -64.6% |
净利率CARRGILD
| Q4 25 | 1.1% | 27.5% | ||
| Q3 25 | 7.7% | 39.3% | ||
| Q2 25 | 9.7% | 27.7% | ||
| Q1 25 | 7.9% | 19.7% | ||
| Q4 24 | 70.3% | 23.6% | ||
| Q3 24 | 7.5% | 16.6% | ||
| Q2 24 | 34.9% | 23.2% | ||
| Q1 24 | 4.4% | -62.4% |
每股收益（稀释后）CARRGILD
| Q4 25 | $0.07 | $1.75 | ||
| Q3 25 | $0.50 | $2.43 | ||
| Q2 25 | $0.68 | $1.56 | ||
| Q1 25 | $0.47 | $1.04 | ||
| Q4 24 | $2.82 | $1.43 | ||
| Q3 24 | $0.49 | $1.00 | ||
| Q2 24 | $2.55 | $1.29 | ||
| Q1 24 | $0.29 | $-3.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $68.0M |
| 总债务越低越好 | $11.4B | $24.9B |
| 股东权益账面价值 | $14.1B | $22.7B |
| 总资产 | $37.2B | $59.0B |
| 负债/权益比越低杠杆越低 | 0.80× | 1.10× |
8季度趋势，按日历期对齐
现金及短期投资CARRGILD
| Q4 25 | $1.6B | $68.0M | ||
| Q3 25 | $1.4B | $19.0M | ||
| Q2 25 | $1.8B | $69.0M | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $4.0B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.9B | — | ||
| Q1 24 | $1.3B | — |
总债务CARRGILD
| Q4 25 | $11.4B | $24.9B | ||
| Q3 25 | $11.3B | $24.9B | ||
| Q2 25 | $11.3B | $24.9B | ||
| Q1 25 | $11.1B | $25.0B | ||
| Q4 24 | $11.0B | $26.7B | ||
| Q3 24 | $10.3B | $23.2B | ||
| Q2 24 | $11.3B | $23.3B | ||
| Q1 24 | $15.6B | $25.2B |
股东权益CARRGILD
| Q4 25 | $14.1B | $22.7B | ||
| Q3 25 | $14.8B | $21.5B | ||
| Q2 25 | $15.0B | $19.7B | ||
| Q1 25 | $14.2B | $19.2B | ||
| Q4 24 | $14.4B | $19.3B | ||
| Q3 24 | $15.0B | $18.5B | ||
| Q2 24 | $14.1B | $18.3B | ||
| Q1 24 | $11.9B | $17.5B |
总资产CARRGILD
| Q4 25 | $37.2B | $59.0B | ||
| Q3 25 | $38.1B | $58.5B | ||
| Q2 25 | $38.5B | $55.7B | ||
| Q1 25 | $36.4B | $56.4B | ||
| Q4 24 | $37.4B | $59.0B | ||
| Q3 24 | $40.2B | $54.5B | ||
| Q2 24 | $40.4B | $53.6B | ||
| Q1 24 | $40.8B | $56.3B |
负债/权益比CARRGILD
| Q4 25 | 0.80× | 1.10× | ||
| Q3 25 | 0.76× | 1.16× | ||
| Q2 25 | 0.76× | 1.27× | ||
| Q1 25 | 0.78× | 1.30× | ||
| Q4 24 | 0.77× | 1.38× | ||
| Q3 24 | 0.69× | 1.26× | ||
| Q2 24 | 0.80× | 1.28× | ||
| Q1 24 | 1.31× | 1.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.0B | $3.3B |
| 自由现金流经营现金流 - 资本支出 | $909.0M | $3.1B |
| 自由现金流率自由现金流/营收 | 18.8% | 39.4% |
| 资本支出强度资本支出/营收 | 2.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 19.62× | 1.52× |
| 过去12个月自由现金流最近4个季度 | $2.1B | $9.5B |
8季度趋势，按日历期对齐
经营现金流CARRGILD
| Q4 25 | $1.0B | $3.3B | ||
| Q3 25 | $341.0M | $4.1B | ||
| Q2 25 | $649.0M | $827.0M | ||
| Q1 25 | $483.0M | $1.8B | ||
| Q4 24 | $132.0M | $3.0B | ||
| Q3 24 | $-269.0M | $4.3B | ||
| Q2 24 | $660.0M | $1.3B | ||
| Q1 24 | $40.0M | $2.2B |
自由现金流CARRGILD
| Q4 25 | $909.0M | $3.1B | ||
| Q3 25 | $224.0M | $4.0B | ||
| Q2 25 | $568.0M | $720.0M | ||
| Q1 25 | $420.0M | $1.7B | ||
| Q4 24 | $-85.0M | $2.8B | ||
| Q3 24 | $-356.0M | $4.2B | ||
| Q2 24 | $549.0M | $1.2B | ||
| Q1 24 | $-64.0M | $2.1B |
自由现金流率CARRGILD
| Q4 25 | 18.8% | 39.4% | ||
| Q3 25 | 4.0% | 51.0% | ||
| Q2 25 | 9.3% | 10.2% | ||
| Q1 25 | 8.0% | 24.8% | ||
| Q4 24 | -2.3% | 37.4% | ||
| Q3 24 | -5.9% | 55.2% | ||
| Q2 24 | 8.2% | 17.2% | ||
| Q1 24 | -1.0% | 31.6% |
资本支出强度CARRGILD
| Q4 25 | 2.7% | 2.6% | ||
| Q3 25 | 2.1% | 1.9% | ||
| Q2 25 | 1.3% | 1.5% | ||
| Q1 25 | 1.2% | 1.6% | ||
| Q4 24 | 6.0% | 1.9% | ||
| Q3 24 | 1.5% | 1.9% | ||
| Q2 24 | 1.7% | 1.9% | ||
| Q1 24 | 1.7% | 1.6% |
现金转化率CARRGILD
| Q4 25 | 19.62× | 1.52× | ||
| Q3 25 | 0.80× | 1.35× | ||
| Q2 25 | 1.10× | 0.42× | ||
| Q1 25 | 1.17× | 1.34× | ||
| Q4 24 | 0.05× | 1.67× | ||
| Q3 24 | -0.60× | 3.44× | ||
| Q2 24 | 0.28× | 0.82× | ||
| Q1 24 | 0.15× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CARR
| Products | $4.1B | 86% |
| Services | $699.0M | 14% |
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
